[76] found no evidence of increased risk of suicidal ideation and self-injury associated with GLP-1 RAs compared to SGLT-2 inhibitors in individuals with T2DM and obesity, based on data from the Valencia Health System Integrated Database (VID) (per-protocol analysis: HR, 1.04
This evidence prompted medical societies (such as the American Diabetes Association) to include GLP-1 in their diabetes care recommendations
In the case of many large employer plans, insurance companies leave the choice up to the employer
Each profile covers mechanism, molecule architecture, sponsor / ownership, clinical status, known efficacy and safety data, differentiation versus the class, and IP positioning
AlphaGen products are supplied strictly for research use only
Buy in Canada Research use only TRIPLE RECEPTOR AGONIST $50 CAD / 10mg vial Purity (HPLC): 99.6% A next-generation peptide targeting GLP-1, GIP, and glucagon receptors, studied in metabolic and glycemic research